CCR5 status and metastatic progression in colorectal cancer

References

• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964. doi:10.1126/science.1129139.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Galon J, Dieu-Nosjean MC, Cremer I, Fisson S, Damotte D, Pagès F, Tartour E, Sautès-Fridman C. Immune infiltration in human cancer: prognostic significance and disease control. Curr Top Microbiol Immunol. 2011;344:1–24. doi:10.1007/82_2010_46.
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Fridman WH, Galon J. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol. 2011;33:335–340. doi:10.1007/s00281-011-0264-x.
   PubMed Web of Science ®Google Scholar
• Becht E, Giraldo NA, Germain C, de Reynies A, Laurent-Puig P, Zucman-Rossi J, Dieu-Nosjean M-C, Sautès-Fridman C, Fridman WH. Immune contexture, immunoscore, and malignant cell molecular subgroups for prognostic and theranostic classifications of cancers. Adv Immunol. 2016;130:95–190. doi:10.1016/bs.ai.2015.12.002.
   PubMed Web of Science ®Google Scholar
• Pagès F, Mlecnik B, Marliot F, Bindea G, Ou F-S, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. The Lancet. 2018;391:2128–2139. doi:10.1016/S0140-6736(18)30789-X.
   PubMed Web of Science ®Google Scholar
• Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, Pommerencke T, von Knebel DM, Folprecht G, Luber B, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 2011;71:5670–5677. doi:10.1158/0008-5472.CAN-11-0268.
   PubMed Web of Science ®Google Scholar
• Tanis E, Julie C, Emile JF, Mauer M, Nordlinger B, Aust D, Roth A, Lutz MP, Gruenberger T, Wrba F, et al. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. Eur J Cancer. 2015;51:2708–2717. doi:10.1016/j.ejca.2015.08.014.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success?. J Clin Invest. 2008;118:1991–2001. doi:10.1172/JCI35180.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med. 2005;202:1075–1085. doi:10.1084/jem.20051511.
   PubMed Web of Science ®Google Scholar
• Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, Geilich M, Winkels G, Traggiai E, Casati A, et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol. 2010;40:22–35. doi:10.1002/eji.200939903.
   PubMed Web of Science ®Google Scholar
• Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest. 2006;116:2777–2790. doi:10.1172/JCI28828.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science. 2013;339:286–291. doi:10.1126/science.1232227.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Zitvogel L, Fridman WH. Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy? Oncoimmunology. 2015;4:e1058597. doi:10.1080/2162402X.2015.1058597.
   PubMed Web of Science ®Google Scholar
• Asaoka Y, Ijichi H, Koike K. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;373:1979. doi:10.1056/NEJMc1510353.
   PubMed Web of Science ®Google Scholar
• Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, et al. Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients. Cancer Cell. 2016;29:587–601. doi:10.1016/j.ccell.2016.03.005.
   PubMed Web of Science ®Google Scholar
• Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal. 2004;16:1201–1210. doi:10.1016/j.cellsig.2004.04.007.
   PubMed Web of Science ®Google Scholar
• Gallo RC, Lusso P. Chemokines and HIV infection. Curr Opin Infect Dis. 1997;10:12–17. doi:10.1097/00001432-199702000-00004.
   Web of Science ®Google Scholar
• Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381:661–666. doi:10.1038/381661a0.
   PubMed Web of Science ®Google Scholar
• Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996;85:1135–1148.
   PubMed Web of Science ®Google Scholar
• Kim MB, Giesler KE, Tahirovic YA, Truax VM, Liotta DC, Wilson LJ. CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV. Expert Opin Investig Drugs. 2016;25:1377–1392. doi:10.1080/13543784.2016.1254615.
   PubMed Web of Science ®Google Scholar
• Zhang J, Gao X, Martin J, Rosa B, Chen Z, Mitreva M, Henrich T, Kuritzkes D, Ratner L. Evolution of coreceptor utilization to escape CCR5 antagonist therapy. Virology. 2016;494:198–214. doi:10.1016/j.virol.2016.04.010.
   PubMed Web of Science ®Google Scholar
• McNiff T, Dezube BJ. CCR5 antagonists in the treatment of HIV-infected persons: is their cancer risk increased, decreased, or unchanged. AIDS Read. 2009;19:218–22, 24.
   PubMedGoogle Scholar
• Henrich TJ, Hanhauser E, Hu Z, Stellbrink HJ, Noah C, Martin JN, Deeks SG, Kuritzkes DR, Pereyra F. Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Delta32. Aids. 2015;29:867–876. doi:10.1097/QAD.0000000000000629.
   PubMed Web of Science ®Google Scholar
• Quillent C, Oberlin E, Braun J, Rousset D, Gonzalez-Canali G, Métais P, Montagnier L, Virelizier J-L, Arenzana-Seisdedos F, Beretta A. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. The Lancet. 1998;351:14–18. doi:10.1016/S0140-6736(97)09185-X.
   PubMed Web of Science ®Google Scholar
• Ying H, Wang J, Gao X. CCL5-403, CCR5-59029, and Delta32 polymorphisms and cancer risk: a meta-analysis based on 20,625 subjects. Tumour Biol. 2014;35:5895–5904. doi:10.1007/s13277-014-1780-9.
   PubMedGoogle Scholar
• Singh SK, Mishra MK, Eltoum I-EA, Bae S, Lillard JW, Singh R. CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells. Sci Rep. 2018;8:1323. doi:10.1038/s41598-018-19643-0.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu T, Yang N, Xu S, Li X, Wang D. Hypoxia and macrophages promote glioblastoma invasion by the CCL4-CCR5 axis. Oncol Rep. 2016;36:3522–3528. doi:10.3892/or.2016.5171.
   PubMed Web of Science ®Google Scholar
• Velasco-Velazquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, Pestell RG. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 2012;72:3839–3850. doi:10.1158/0008-5472.CAN-11-3917.
   PubMed Web of Science ®Google Scholar
• Gao D, Rahbar R, Fish EN. CCL5 activation of CCR5 regulates cell metabolism to enhance proliferation of breast cancer cells. Open Biol. 2016;6:160122. doi:10.1098/rsob.160122.
   PubMed Web of Science ®Google Scholar
• Tanabe Y, Sasaki S, Mukaida N, Baba T. Blockade of the chemokine receptor, CCR5, reduces the growth of orthotopically injected colon cancer cells via limiting cancerassociated fibroblast accumulation. Oncotarget. 2016;7:48335. doi:10.18632/oncotarget.v7i30.
   PubMedGoogle Scholar
• Mencarelli A, Graziosi L, Renga B, Cipriani S, D’Amore C, Francisci D, Bruno A, Baldelli F, Donini A, Fiorucci S. CCR5 antagonism by maraviroc reduces the potential for gastric cancer cell dissemination. Transl Oncol. 2013;6:784–793.
   PubMed Web of Science ®Google Scholar
• Musha H, Ohtani H, Mizoi T, Kinouchi M, Nakayama T, Shiiba K, Miyagawa K, Nagura H, Yoshie O, Sasaki I. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int J Cancer. 2005;116:949–956. doi:10.1002/ijc.21135.
   PubMed Web of Science ®Google Scholar
• Findeisen P, Kloor M, Merx S, Sutter C, Woerner SM, Dostmann N, Benner A, Dondog B, Pawlita M, Dippold W, et al. T25 repeat in the 3’ untranslated region of the CASP2 gene: a sensitive and specific marker for microsatellite instability in colorectal cancer. Cancer Res. 2005;65:8072–8078. doi:10.1158/0008-5472.CAN-04-4146.
   PubMed Web of Science ®Google Scholar
• Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878. doi:10.1038/s41598-017-17204-5.
   PubMed Web of Science ®Google Scholar
• Kather JN, Suarez-Carmona M, Charoentong P, Weis CA, Hirsch D, Bankhead P. Topography of cancer-associated immune cells in human solid tumors. Elife. 2018 Sep 4;7:pii:e36967. doi:10.7554/eLife.36967.
   Google Scholar
• Abdi R, Tran TB, Sahagun-Ruiz A, Murphy PM, Brenner BM, Milford EL, McDermott DH. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol. 2002;13:754–758.
   PubMed Web of Science ®Google Scholar
• Jones DT, Hutter B, Jager N, Korshunov A, Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M, Quang DAK, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013;45:927–932. doi:10.1038/ng.2682.
   PubMed Web of Science ®Google Scholar
• Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14:178–192. doi:10.1093/bib/bbs017.
   PubMed Web of Science ®Google Scholar
• Kather JN, Halama N. Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer. Br J Cancer. 2019;120:871–882. doi:10.1038/s41416-019-0441-6.
   PubMed Web of Science ®Google Scholar
• Zimmermann T, Moehler M, Gockel I, Sgourakis GG, Biesterfeld S, Müller M, Berger MR, Lang H, Galle PR, Schimanski CC. Low expression of chemokine receptor CCR5 in human colorectal cancer correlates with lymphatic dissemination and reduced CD8+ T-cell infiltration. Int J Colorectal Dis. 2010;25:417–424. doi:10.1007/s00384-009-0868-y.
   PubMed Web of Science ®Google Scholar
• Nishikawa G, Kawada K, Nakagawa J, Toda K, Ogawa R, Inamoto S, Mizuno R, Itatani Y, Sakai Y. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression via CCR5. Cell Death Dis. 2019;10:264. doi:10.1038/s41419-019-1508-2.
   PubMed Web of Science ®Google Scholar
• Cambien B, Richard-Fiardo P, Karimdjee BF, Martini V, Ferrua B, Pitard B, Schmid-Antomarchi H, Schmid-Alliana A, Glinskii VV. CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinoma. PLoS One. 2011;6:e28842. doi:10.1371/journal.pone.0028842.
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449:557–563. doi:10.1038/nature06188.
   PubMed Web of Science ®Google Scholar
• Sicoli D, Jiao X, Ju X, Velasco-Velazquez M, Ertel A, Addya S, Li Z, Andò S, Fatatis A, Paudyal B, et al. CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines. Cancer Res. 2014;74:7103–7114. doi:10.1158/0008-5472.CAN-14-0612.
   PubMed Web of Science ®Google Scholar
• Long H, Xiang T, Qi W, Huang J, Chen J, He L, Liang Z, Guo B, Li Y, Xie R, et al. CD133+ ovarian cancer stem-like cells promote non-stem cancer cell metastasis via CCL5 induced epithelial-mesenchymal transition. Oncotarget. 2015;6:5846–5859. doi:10.18632/oncotarget.3462.
   PubMedGoogle Scholar
• D’Esposito V, Liguoro D, Ambrosio MR, Collina F, Cantile M, Spinelli R, Raciti GA, Miele C, Valentino R, Campiglia P, et al. Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5. Oncotarget. 2016;7:24495–24509. doi:10.18632/oncotarget.8336.
   PubMedGoogle Scholar
• Alkhatib G. The biology of CCR5 and CXCR4. Curr Opin HIV AIDS. 2009;4:96–103. doi:10.1097/COH.0b013e328324bbec.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010;21:27–39. doi:10.1016/j.cytogfr.2009.11.007.
   PubMed Web of Science ®Google Scholar
• Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382:722–725. doi:10.1038/382722a0.
   PubMed Web of Science ®Google Scholar
• Pereira RW, Pires ER, Duarte APM, Torloni H, Proietti AB, de Moura RP, Proietti AB, Simpson AJG, Pena SDJ. Frequency of the CCR5 32 allele in Brazilians: a study in colorectal cancer and in HTLV-I infection. Genet Mol Biol. 2000;23:4. doi:10.1590/S1415-47572000000300003.
   Web of Science ®Google Scholar
• O’Brien SJ, Moore JP. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev. 2000;177:99–111.
   PubMed Web of Science ®Google Scholar
• Marmor M, Sheppard HW, Donnell D, Bozeman S, Celum C, Buchbinder S, Koblin B, Seage GR. Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr. 2001;27:472–481.
   PubMed Web of Science ®Google Scholar
• Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta SD, Goldstein SC, Stadtmauer EA, Smith J, Bailey S, et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med. 2012;367:135–145. doi:10.1056/NEJMoa1201248.
   PubMed Web of Science ®Google Scholar
• Halvorsen EC, Hamilton MJ, Young A, Wadsworth BJ, LePard NE, Lee HN, Firmino N, Collier JL, Bennewith KL. Maraviroc decreases CCL8-mediated migration of CCR5+ regulatory T cells and reduces metastatic tumor growth in the lungs. Oncoimmunology. 2016;5:e1150398. doi:10.1080/2162402X.2016.1150398.
   PubMed Web of Science ®Google Scholar
• Nie Y, Huang H, Guo M, Chen J, Wu W, Li W, Xu X, Lin X, Fu W, Yao Y,et al. Breast phyllodes tumors recruit and repolarize tumor-associated macrophages via secreting CCL5 to promote malignant progression, which can be inhibited by CCR5 inhibition therapy. Clin Cancer Res. 2019.
   PubMed Web of Science ®Google Scholar
• Casagrande N, Borghese C, Visser L, Mongiat M, Colombatti A, Aldinucci D. CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth. Haematologica. 2019;104:564–575. doi:10.3324/haematol.2018.196725.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Casagrande N. Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer. Int J Mol Sci. 2018;19:1477. doi:10.3390/ijms19051477.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Borras JM, Castells A, Ciardiello F, Ducreux M, Haq A, Schmoll H-J, Tabernero J. Improving outcomes in colorectal cancer: where do we go from here?. Eur J Cancer. 2013;49:2476–2485. doi:10.1016/j.ejca.2013.03.026.
   PubMed Web of Science ®Google Scholar
• Flemer B, Lynch DB, Brown JMR, Jeffery IB, Ryan FJ, Claesson MJ, O’Riordain M, Shanahan F, O’Toole PW. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut. 2017;66:633–643. doi:10.1136/gutjnl-2015-309595.
   PubMed Web of Science ®Google Scholar